CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
Results of Operations and Financial Condition.
On March 18, 2019, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended January31, 2019. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
The following exhibit is filed herewith:
Exhibit No.
|
99.1 |
Press Release Dated March 18, 2019
|
CHAMPIONS ONCOLOGY, INC. Exhibit
EX-99.1 2 csbr8-k1312019exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 NEWSOne University Plaza,…
To view the full exhibit click here
About CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR)
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank.
